Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Biliary Tract Diseases

Free Subscription Articles published in J Hepatol Retrieve available abstracts of 162 articles: HTML format

Single Articles

May 2024
1. KRAUSE J, Schramm C
   Multi-omics characterization of healthy and PSC human liver - what we knew and what we have learned.
   J Hepatol. 2024;80:681-683.
   PubMed    
   
   
   
2. ANDREWS TS, Nakib D, Perciani CT, Ma XZ, et al
   Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver.
   J Hepatol. 2024;80:730-743.
   PubMed     Abstract available
   
   
   April 2024
3. YANG L, Niu K, Wang J, Shen W, et al
   Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD.
   J Hepatol. 2024 Apr 26:S0168-8278(24)00278-2. doi: 10.1016/j.jhep.2024.
   PubMed     Abstract available
   
   
   March 2024
4. LEMAIGRE FP
   Planar cell polarity is crucial for proper morphogenesis of the bile ducts.
   J Hepatol. 2024 Mar 26:S0168-8278(24)00217-4. doi: 10.1016/j.jhep.2024.
   PubMed    
   
   
   
5. XU L, Zhang Y, Lin Z, Deng X, et al
   FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
   J Hepatol. 2024 Mar 18:S0168-8278(24)00199-5. doi: 10.1016/j.jhep.2024.
   PubMed     Abstract available
   
   
   
6. RAAB M, Christodoulou E, Krishnankutty R, Gradinaru A, et al
   Van Gogh-like 2 is essential for the architectural patterning of the mammalian biliary tree.
   J Hepatol. 2024 Mar 7:S0168-8278(24)00149-1. doi: 10.1016/j.jhep.2024.
   PubMed     Abstract available
   
   
   
7. LIM YZ, Zhu M, Wang Y, Sharma T, et al
   Pkd1l1-deficiency drives biliary atresia through ciliary dysfunction in biliary epithelial cells.
   J Hepatol. 2024 Mar 7:S0168-8278(24)00151-X. doi: 10.1016/j.jhep.2024.
   PubMed     Abstract available
   
   
   
8. TOMLINSON JL, Li B, Yang J, Loeuillard E, et al
   Syngeneic Murine Models with Distinct Immune Microenvironments Represent Subsets of Human Intrahepatic Cholangiocarcinoma.
   J Hepatol. 2024 Mar 6:S0168-8278(24)00127-2. doi: 10.1016/j.jhep.2024.
   PubMed     Abstract available
   
   
   February 2024
9. YANG Y, Wang J, Wan J, Cheng Q, et al
   PTEN Deficiency Induces an Extrahepatic Cholangitis-Cholangiocarcinoma Continuum via Aurora kinase A in Mice.
   J Hepatol. 2024 Feb 28:S0168-8278(24)00138-7. doi: 10.1016/j.jhep.2024.
   PubMed     Abstract available
   
   
   January 2024
10. FAN X, Yang F, Zhou L, Yang L, et al
    Mycophenolate mofetil for the induction of remission in primary biliary cholangitis with predominant features of autoimmune hepatitis.
    J Hepatol. 2024 Jan 31:S0168-8278(24)00097-7. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
11. TANG R, Li Y, Chen R, Ma X, et al
    Reply to "ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort".
    J Hepatol. 2024 Jan 30:S0168-8278(24)00058-8. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
12. NAYAGAM JS, Miquel R, Thompson RJ, Joshi D, et al
    Genetic cholestasis in children and adults.
    J Hepatol. 2024 Jan 30:S0168-8278(23)05305-9. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
13. TRAMPERT DC, Beuers U
    A beneficial response of fetal wound healing gone bad in the bile duct: The overarching cause of biliary atresia?
    J Hepatol. 2024 Jan 4:S0168-8278(23)05372-2. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
14. ZHENG C, Wang L, Zou T, Lian S, et al
    Ileitis promotes MASLD progression via bile acid modulation and enhanced TGR5 signaling in ileal CD8+ T cells.
    J Hepatol. 2024 Jan 3:S0168-8278(24)00004-7. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    November 2023
15. KRUK B, Liebe R, Weber SN, Milkiewicz P, et al
    ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort.
    J Hepatol. 2023 Nov 28:S0168-8278(23)05290-X. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
16. FICKERT P
    Detour of bile acids routes as therapeutic roadmap for cholemic nephropathy.
    J Hepatol. 2023 Nov 25:S0168-8278(23)05283-2. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
17. DIPERI TP, Zhao M, Evans KW, Varadarajan K, et al
    Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
    J Hepatol. 2023 Nov 14:S0168-8278(23)05274-1. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
18. VAN MUNSTER KN, Bergquist A, Ponsioen CY
    Inflammatory bowel disease and primary sclerosing cholangitis: One disease or two?
    J Hepatol. 2023 Nov 6:S0168-8278(23)05158-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
19. GHALLAB A, Gonzalez D, Strangberg E, Hofmann U, et al
    Inhibition of the Renal Apical Sodium Dependent Bile Acid Transporter Prevents Cholemic Nephropathy in Mice with Obstructive Cholestasis.
    J Hepatol. 2023 Nov 6:S0168-8278(23)05235-2. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    October 2023
20. DE JONG IEM, Theise ND, Wells RG
    The space of Mall confirmed in humans: a response to "Portal venous branches as an anatomic railroad for a gut-bile duct axis".
    J Hepatol. 2023 Oct 9:S0168-8278(23)05155-3. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
21. TRUSSONI CE, LaRusso NF
    Macrophages make a difference in cholestatic liver diseases - but how?
    J Hepatol. 2023 Oct 9:S0168-8278(23)05149-8. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
22. MALAKAR S, Mishra P, Paturu R, Verma R, et al
    Primary sclerosing cholangitis with high immunoglobulin-G4.
    J Hepatol. 2023 Oct 7:S0168-8278(23)05153-X. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    September 2023
23. 
    Corrigendum to "EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma" [J Hepatol (79) (2023) 181-208].
    J Hepatol. 2023 Sep 23:S0168-8278(23)05092-4. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
24. 
    Corrigendum to "EASL clinical practice guidelines on sclerosing cholangitis" [J Hepatol (77) 761-806].
    J Hepatol. 2023 Sep 19:S0168-8278(23)05091-2. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
25. ABERG F, Sallinen V, Tuominen S, Adam R, et al
    Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis - a propensity-score matched intention-to-treat analysis.
    J Hepatol. 2023 Sep 16:S0168-8278(23)05100-0. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    August 2023
26. CHEN R, Huang B, Lian M, Wei Y, et al
    A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.
    J Hepatol. 2023 Aug 31:S0168-8278(23)05069-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
27. LIMOUSIN W, Laurent-Puig P, Ziol M, Ganne-Carrie N, et al
    Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
    J Hepatol. 2023 Aug 28:S0168-8278(23)05070-5. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
28. DE JONG IEM, Hunt ML, Chen D, Du Y, et al
    A fetal wound healing program after intrauterine bile duct injury may contribute to biliary atresia.
    J Hepatol. 2023 Aug 21:S0168-8278(23)05060-2. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
29. KERSTEN R, Trampert DC, Herta T, Hubers LM, et al
    IgG4-related cholangitis - a mimicker of fibrosing and malignant cholangiopathies.
    J Hepatol. 2023 Aug 18:S0168-8278(23)05058-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
30. GLESSNER JT, Ningappa MB, Ngo KA, Zahid M, et al
    Biliary atresia is associated with polygenic susceptibility in ciliogenesis and planar polarity effector genes.
    J Hepatol. 2023 Aug 10:S0168-8278(23)05040-7. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
31. ROMA K, Mohammed S, Sieck B, Naik K, et al
    Kratom-induced acute liver injury: A case study and the importance of herbal supplement regulation.
    J Hepatol. 2023;79:581-584.
    PubMed     Abstract available
    
    
    July 2023
32. DE MARTIN E, Laurent-Bellue A, Routier E, Samuel D, et al
    Acute cholestatic hepatitis in a patient with metastatic melanoma.
    J Hepatol. 2023;79:e13-e15.
    PubMed    
    
    
    
33. D'ARTISTA L, Moschopoulou AA, Barozzi I, Craig AJ, et al
    MYC determines lineage commitment in KRAS-driven primary liver cancer development.
    J Hepatol. 2023;79:141-149.
    PubMed     Abstract available
    
    
    June 2023
34. ROMEO M, Dallio M, Federico A
    Multidrug Resistance Protein 6 (ABCC6/MRP6) loss of function causing Pseudoxanthoma elasticum (PXE) is associated with Low-Phospholipid Associated Cholelithiasis (LPAC) features: is it time to reconsider the MRP6 role in bile secretion and LPAC geneti
    J Hepatol. 2023 Jun 29:S0168-8278(23)04936-X. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
35. ARINO S, Aguilar-Bravo B, Coll M, Lee WY, et al
    Ductular reaction-associated neutrophils promote biliary epithelium proliferation in chronic liver disease.
    J Hepatol. 2023 Jun 20:S0168-8278(23)00423-3. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
36. ALMAAS R, Atneosen-Asegg M, Ytre-Arne ME, Melheim M, et al
    Aagenaes syndrome/lymphedema cholestasis syndrome 1 is caused by a founder variant in the 5'-untranslated region of UNC45A.
    J Hepatol. 2023 Jun 14:S0168-8278(23)00410-5. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
37. BRAADLAND PR, Bergquist A, Kummen M, Bossen L, et al
    Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation.
    J Hepatol. 2023 Jun 14:S0168-8278(23)00415-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
38. LATTANZI B, Covotta F, Cardinale V
    The Potential Role Of Endoscopy Ultrasound In Primary Sclerosing Cholangitis.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00404-X. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    May 2023
39. TOMLINSON JL, Valle JW, Ilyas SI
    Immunobiology of Cholangiocarcinoma.
    J Hepatol. 2023 May 16:S0168-8278(23)00338-0. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
40. BOLDUAN F, Geisel D, Pahl S, Wree A, et al
    Painless jaundice with segmental obstructive cholestasis.
    J Hepatol. 2023 May 9:S0168-8278(23)00209-X. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    April 2023
41. GRADY J, Clifford C, Treadwell MC, Parikh ND, et al
    The Use of Fenofibrate for Intrahepatic Cholestasis of Pregnancy.
    J Hepatol. 2023 Apr 19:S0168-8278(23)00237-4. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
42. DANA J, Debray D, Vilgrain V
    Reply to: "The effects of CFTR modulator therapies on liver stiffness and bile flow: a single centre experience".
    J Hepatol. 2023 Apr 10:S0168-8278(23)00222-2. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
43. FICKERT P, Lin AC, Ritschl H, Hammer N, et al
    Portal venous branches as an anatomic railroad for a gut-bile duct-axis.
    J Hepatol. 2023 Apr 10:S0168-8278(23)00221-0. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    March 2023
44. 
    EASL-ILCA Clinical Practice Guidelines on Intrahepatic Cholangiocarcinoma.
    J Hepatol. 2023 Mar 22:S0168-8278(23)00185-X. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
45. RICCIUTO A, Kamath BM, Hirschfield GM, Trivedi PJ, et al
    Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: a coming of age or an age-ist problem?
    J Hepatol. 2023 Mar 2:S0168-8278(23)00162-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
46. JUANOLA A, Moreta MJ, Caballero G, Diaz A, et al
    Fever and cholestasis in a male.
    J Hepatol. 2023;78:e90-e92.
    PubMed    
    
    
    
47. LAPITZ A, Azkargorta M, Milkiewicz P, Olaizola P, et al
    Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma.
    J Hepatol. 2023 Mar 1:S0168-8278(23)00159-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    February 2023
48. CALVO PL, Giugliano L, Evangelista A, Bignamini E, et al
    The effects of CFTR modulator therapies on liver stiffness and bile flow: a single centre experience.
    J Hepatol. 2023 Feb 17:S0168-8278(23)00094-6. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
49. CADAMURO M, Al-Taee A, Gonda TA
    Advanced endoscopy meets molecular diagnosis of cholangiocarcinoma.
    J Hepatol. 2023 Feb 3:S0168-8278(23)00080-6. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
50. DUWE L, Munoz-Garrido P, Lewinska M, Lafuente-Barquero J, et al
    MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells.
    J Hepatol. 2023;78:364-375.
    PubMed     Abstract available
    
    
    January 2023
51. SPOSITO C, Cucchetti A, Mazzaferro V
    Survival Benefit Of Lymphadenectomy For Intrahepatic Cholangiocarcinoma: It Might Be Gold Even If It Does Not Glitter.
    J Hepatol. 2023 Jan 31:S0168-8278(23)00073-9. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
52. JI R, Chen J, Xie Y, Dou X, et al
    Multi-omics profiling of cholangiocytes reveals sex-specific chromatin state dynamics during hepatic cystogenesis in polycystic liver disease.
    J Hepatol. 2023 Jan 18:S0168-8278(23)00015-6. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
53. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    Corrigendum to: "An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs" [J Hepatol 75 (2021) 572-581].
    J Hepatol. 2023 Jan 11:S0168-8278(22)03321-9. doi: 10.1016/j.jhep.2022.
    PubMed    
    
    
    
54. MAGYAR CTJ, Beldi G, Banz V
    Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma - Letter to the editor.
    J Hepatol. 2023 Jan 5:S0168-8278(22)03474-2. doi: 10.1016/j.jhep.2022.
    PubMed    
    
    
    December 2022
55. KOERKAMP BG, Clavien PA, Polak WG
    Surgical resection for intrahepatic cholangiocarcinoma - can we really improve survival by resecting more lymph nodes?
    J Hepatol. 2022 Dec 23:S0168-8278(22)03327-X. doi: 10.1016/j.jhep.2022.
    PubMed    
    
    
    
56. HARTMANN P, Schnabl B
    Fungal infections and the fungal microbiome in hepatobiliary disorders.
    J Hepatol. 2022 Dec 21:S0168-8278(22)03415-8. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
57. KENDRE G, Murugesan K, Brummer T, Segatto O, et al
    Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Dec 14:S0168-8278(22)03328-1. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    November 2022
58. VILLARD C, Friis-Liby I, Rorsman F, Said K, et al
    Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis.
    J Hepatol. 2022 Nov 18:S0168-8278(22)03303-7. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
59. MERTERS J, Lamarca A
    Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma.
    J Hepatol. 2022 Nov 15. pii: S0168-8278(22)03296.
    PubMed     Abstract available
    
    
    October 2022
60. SPOSITO C, Ratti F, Cucchetti A, Ardito F, et al
    Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Oct 31. pii: S0168-8278(22)03158.
    PubMed     Abstract available
    
    
    
61. NEVENS F, Trauner M, Manns MP
    Primary biliary cholangitis as a roadmap for the development of novel treatments of cholestatic liver diseases.
    J Hepatol. 2022 Oct 19. pii: S0168-8278(22)03143.
    PubMed     Abstract available
    
    
    
62. OKAWA Y, Iwasaki Y, Johnson TA, Ebata N, et al
    Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer.
    J Hepatol. 2022 Oct 12. pii: S0168-8278(22)03137.
    PubMed     Abstract available
    
    
    
63. LEE SK, Kwon JH, Yoon N, Lee SH, et al
    Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination.
    J Hepatol. 2022;77:1209-1211.
    PubMed    
    
    
    September 2022
64. CONBOY CB, Yonkus JA, Buckarma EH, Mun DG, et al
    LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.
    J Hepatol. 2022 Sep 23. pii: S0168-8278(22)03121.
    PubMed     Abstract available
    
    
    
65. HARDING JJ, Khalil DN, Fabris L, Abou-Alfa GK, et al
    Rational Development of Combination Therapies in Biliary Tract Cancers.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03078.
    PubMed     Abstract available
    
    
    
66. ARECHEDERRA M, Fernandez-Barrena MG
    Hepatic progenitor cells, senescence and IL6 as the main players in combined hepatocellular-cholangiocarcinoma development.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03114.
    PubMed    
    
    
    
67. BJORKSTROM NK
    Immunobiology of the biliary tract system.
    J Hepatol. 2022 Sep 15. pii: S0168-8278(22)03020.
    PubMed     Abstract available
    
    
    August 2022
68. ZHANG R, Huang J, Shan J, Chen Y, et al
    Peripheral blood CD177(+) cells as an early diagnostic marker for biliary atresia: a prospective multicentre study in pediatric patients with cholestasis.
    J Hepatol. 2022 Aug 19. pii: S0168-8278(22)03005.
    PubMed    
    
    
    
69. ROSENBERG N, Van Haele M, Lanton T, Brashi N, et al
    Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL6 trans-signaling.
    J Hepatol. 2022 Aug 18. pii: S0168-8278(22)02995.
    PubMed     Abstract available
    
    
    
70. KENNEDY L, Carpino G, Owen T, Ceci L, et al
    Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes.
    J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02999.
    PubMed     Abstract available
    
    
    
71. CALDERARO J, Di Tommaso L, Maille P, Beaufrere A, et al
    Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
    J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02983.
    PubMed     Abstract available
    
    
    
72. VITHAYATHIL M, Khan SA
    Current epidemiology of cholangiocarcinoma in western countries.
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02988.
    PubMed     Abstract available
    
    
    
73. BOWLUS CL, Levy C, Hirschfield GM
    Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!"
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02990.
    PubMed    
    
    
    July 2022
74. MARJOT T, Eberhardt CS, Boettler T, Belli LS, et al
    Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper.
    J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02942.
    PubMed    
    
    
    
75. ZHANG R, Su L, Fu M, Wang Z, et al
    CD177(+) cells produce neutrophil extracellular traps to promote biliary atresia.
    J Hepatol. 2022 Jul 5. pii: S0168-8278(22)00409.
    PubMed     Abstract available
    
    
    
76. MULLER AL, Casar C, Preti M, Krzikalla D, et al
    Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis.
    J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02923.
    PubMed     Abstract available
    
    
    June 2022
77. CORPECHOT C, Carrat F, Gaouar F, Chau F, et al
    Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
    J Hepatol. 2022 Jun 28. pii: S0168-8278(22)00411.
    PubMed     Abstract available
    
    
    
78. HUANG B, Lyu Z, Qian Q, Chen Y, et al
    NUDT1 promotes the accumulation and longevity of CD103(+) TRM cells in primary biliary cholangitis.
    J Hepatol. 2022 Jun 23. pii: S0168-8278(22)00408.
    PubMed     Abstract available
    
    
    
79. LABIANO I, Agirre-Lizaso A, Olaizola P, Echebarria A, et al
    TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation.
    J Hepatol. 2022 Jun 21. pii: S0168-8278(22)00372.
    PubMed     Abstract available
    
    
    
80. ALVISI G, Termanini A, Soldani C, Portale F, et al
    Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00370.
    PubMed     Abstract available
    
    
    
81. SCHLEGEL A, Porte RJ, Dutkowski P
    Corrigendum to 'Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy' [J Hepatol 76 (2022) 1330-1347].
    J Hepatol. 2022 Jun 16. pii: S0168-8278(22)00353.
    PubMed    
    
    
    
82. HOGDALL D, O'Rourke CJ, Larsen FO, Zarforoushan S, et al
    Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00358.
    PubMed     Abstract available
    
    
    
83. GRAVELY AK, Vibert E, Sapisochin G
    Surgical treatment of intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Jun 5. pii: S0168-8278(22)00017.
    PubMed    
    
    
    
84. SCHLEGEL A, Porte R, Dutkowski P
    Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy.
    J Hepatol. 2022;76:1330-1347.
    PubMed     Abstract available
    
    
    May 2022
85. 
    EASL Clinical Practice Guidelines on Sclerosing Cholangitis.
    J Hepatol. 2022 May 31. pii: S0168-8278(22)00326.
    PubMed    
    
    
    
86. MISHRA AK, Singh SP
    Seladelpar in patients with primary biliary cholangitis: Need a closer look!
    J Hepatol. 2022 May 17. pii: S0168-8278(22)00315.
    PubMed    
    
    
    
87. RAGGI C, Taddei ML, Rae C, Braconi C, et al
    Metabolic Reprogramming in Cholangiocarcinoma.
    J Hepatol. 2022 May 17. pii: S0168-8278(22)00314.
    PubMed     Abstract available
    
    
    
88. GURI Y, Vosbeck J, Dickenmann M, Jetter A, et al
    Exacerbation of Familial Intrahepatic Cholestasis in Conjunction with COVID-19 Vaccination.
    J Hepatol. 2022 May 16. pii: S0168-8278(22)00313.
    PubMed    
    
    
    April 2022
89. LUDDE T, Boulter L
    Joining the dots - NEDDylation in cancer cells regulates the tumour environment in Cholangiocarcinoma.
    J Hepatol. 2022 Apr 28. pii: S0168-8278(22)00253.
    PubMed    
    
    
    March 2022
90. BOWLUS CL, Galambos MR, Aspinall RJ, Hirschfield GM, et al
    A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
    J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00187.
    PubMed     Abstract available
    
    
    
91. SUN R, Zhang Z, Bao R, Guo X, et al
    Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.
    J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00139.
    PubMed     Abstract available
    
    
    
92. WEBER ND, Martinez-Garcia J, Gonzalez-Aseguinolaza G
    Comment on "Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3".
    J Hepatol. 2022;76:749-751.
    PubMed    
    
    
    February 2022
93. OLAIZOLA P, Lee-Law PY, Fernandez-Barrena MG, Alvarez L, et al
    Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models.
    J Hepatol. 2022 Feb 22. pii: S0168-8278(22)00082.
    PubMed     Abstract available
    
    
    
94. GHALLAB A, Hassan R, Hofmann U, Friebel A, et al
    Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity.
    J Hepatol. 2022 Feb 4. pii: S0168-8278(22)00062.
    PubMed     Abstract available
    
    
    January 2022
95. CASOLINO R, Amato F, Rae C, Puttagunta S, et al
    Receptor Tyrosine kinase co-amplification and benefit from HER2 inhibitors in Biliary Tract Cancers.
    J Hepatol. 2022 Jan 27. pii: S0168-8278(22)00025.
    PubMed    
    
    
    December 2021
96. GARRIDO A, Kim E, Teijeiro A, Sanchez PS, et al
    Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis.
    J Hepatol. 2021 Dec 24. pii: S0168-8278(21)02294.
    PubMed     Abstract available
    
    
    
97. IZQUIERDO-SANCHEZ L, Lamarca A, La Casta A, Buettner S, et al
    Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.
    J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02252.
    PubMed     Abstract available
    
    
    
98. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581].
    J Hepatol. 2021 Dec 9. pii: S0168-8278(21)02219.
    PubMed    
    
    
    November 2021
99. DING GY, Ma JQ, Yun JP, Chen X, et al
    Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02178.
    PubMed     Abstract available
    
    
    October 2021
100. HERTA T, Kersten R, Chang JC, Hubers L, et al
     Role of the IgG4-related cholangitis autoantigen annexin A11 in cholangiocyte protection.
     J Hepatol. 2021 Oct 27. pii: S0168-8278(21)02116.
     PubMed     Abstract available
     
     
     
101. KEPPLER D, Beuers U, Trauner M
     A life with bile acids: Alan F. Hofmann (1931-2021).
     J Hepatol. 2021 Oct 14. pii: S0168-8278(21)02081.
     PubMed    
     
     
     
102. LOUIS C, Coulouarn C
     One stone, two birds: circACTN4, a nexus for a coordinated activation of Hippo and Wnt/beta-catenin pathways in cholangiocarcinoma.
     J Hepatol. 2021 Oct 12. pii: S0168-8278(21)02108.
     PubMed    
     
     
     
103. MALLET V
     Reply to: "Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered".
     J Hepatol. 2021;75:990-992.
     PubMed    
     
     
     September 2021
104. CHEN Q, Wang H, Li Z, Li F, et al
     Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.
     J Hepatol. 2021 Sep 9. pii: S0168-8278(21)02025.
     PubMed     Abstract available
     
     
     
105. VUPPALANCHI R, Caldwell SH, Pyrsopoulos N, deLemos AS, et al
     Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
     J Hepatol. 2021 Sep 3. pii: S0168-8278(21)02023.
     PubMed     Abstract available
     
     
     August 2021
106. ZHOU T, Fronhoffs F, Dold L, Strassburg CP, et al
     New-Onset Autoimmune Hepatitis following mRNA Covid-19 Vaccination in a 36-year-old woman with Primary Sclerosing Cholangitis - should we be more vigilant?
     J Hepatol. 2021 Aug 24. pii: S0168-8278(21)02000.
     PubMed    
     
     
     
107. DE JONG IEM, van den Heuvel MC, Wells RG, Porte RJ, et al
     The heterogeneity of the biliary tree.
     J Hepatol. 2021 Aug 19. pii: S0168-8278(21)00251.
     PubMed    
     
     
     July 2021
108. CARPINO G, Cardinale V, Di Giamberardino A, Overi D, et al
     Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.
     J Hepatol. 2021 Jul 27. pii: S0168-8278(21)01947.
     PubMed     Abstract available
     
     
     
109. LODATO F, Larocca A, D'Errico A, Cennamo V, et al
     AN ANUSUAL CASE OF ACUTE CHOLESTATIC HEPATITIS AFTER m-RNABNT162b2 (COMIRNATY) SARS-CoV-2 VACCINE: COINCIDENCE, AUTOIMMUNITY OR DRUG RELATED LIVER INJURY?
     J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01904.
     PubMed    
     
     
     
110. VAQUERO J, Keitel V
     Deciphering FAK in intrahepatic cholangiocarcinoma: a novel therapeutic target?
     J Hepatol. 2021 Jul 9. pii: S0168-8278(21)01902.
     PubMed    
     
     
     June 2021
111. MA L, Wang L, Khatib SA, Chang CW, et al
     Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
     J Hepatol. 2021 Jun 30. pii: S0168-8278(21)01848.
     PubMed     Abstract available
     
     
     
112. VITHAYATHIL M, Bridegwater J, Khan SA
     Medical therapies for intra-hepatic cholangiocarcinoma.
     J Hepatol. 2021 Jun 29. pii: S0168-8278(21)00238.
     PubMed    
     
     
     
113. ZHANG Y, Zuo C, Liu L, Hu Y, et al
     Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer.
     J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00442.
     PubMed     Abstract available
     
     
     
114. CORPECHOT C
     Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
     J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.
     PubMed    
     
     
     
115. WEI G, Cao J, Huang P, An P, et al
     Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3.
     J Hepatol. 2021;74:1416-1428.
     PubMed     Abstract available
     
     
     May 2021
116. SONG X, Xu H, Wang P, Wang J, et al
     Focal Adhesion Kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
     J Hepatol. 2021 May 27. pii: S0168-8278(21)00353.
     PubMed     Abstract available
     
     
     
117. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
     An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs.
     J Hepatol. 2021 May 22. pii: S0168-8278(21)00334.
     PubMed     Abstract available
     
     
     
118. BOULTER L, Ebrahimkhani MR
     Build to understand biliary oncogenesis via organoids and FGFR2 fusion proteins.
     J Hepatol. 2021 May 21. pii: S0168-8278(21)00341.
     PubMed    
     
     
     
119. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
     Erratum to: "Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia" (J Hepatol 2021; 74: 428-441).
     J Hepatol. 2021 May 12. pii: S0168-8278(21)00330.
     PubMed    
     
     
     
120. HYUN J, Al Abo M, Dutta RK, Oh SH, et al
     Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
     J Hepatol. 2021 May 5. pii: S0168-8278(21)00298.
     PubMed     Abstract available
     
     
     April 2021
121. TANAKA A, Hirohara J, Nakano T, Matsumoto K, et al
     Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
     J Hepatol. 2021 Apr 18. pii: S0168-8278(21)00245.
     PubMed     Abstract available
     
     
     
122. REICH M, Spomer L, Klindt C, Fuchs K, et al
     Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
     J Hepatol. 2021 Apr 16. pii: S0168-8278(21)00244.
     PubMed     Abstract available
     
     
     
123. VALLEJO A, Erice O, Entrialgo-Cadierno R, Feliu I, et al
     FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.
     J Hepatol. 2021 Apr 14. pii: S0168-8278(21)00235.
     PubMed     Abstract available
     
     
     March 2021
124. POCH T, Krause J, Casar C, Liwinski T, et al
     Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis.
     J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00219.
     PubMed     Abstract available
     
     
     
125. DELTENRE P, Moreno C, Trepo E
     Progressive cholangiopathy in Covid-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered.
     J Hepatol. 2021 Mar 19. pii: S0168-8278(21)00179.
     PubMed    
     
     
     
126. LI J, Zhu X, Zhang M, Zhang Y, et al
     Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
     J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00177.
     PubMed     Abstract available
     
     
     
127. CRISTINZIANO G, Porru M, Lamberti D, Buglioni S, et al
     FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
     J Hepatol. 2021 Mar 16. pii: S0168-8278(21)00172.
     PubMed     Abstract available
     
     
     
128. MUTANEN A, Lohi J, Merras-Salmio L, Koivusalo A, et al
     Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure.
     J Hepatol. 2021;74:593-602.
     PubMed     Abstract available
     
     
     February 2021
129. SHAHINI E, Ahmed F
     Chronic fatigue should not be overlooked in primary biliary cholangitis.
     J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.
     PubMed    
     
     
     
130. KEIDING S, Frisch K, Hofmann AF
     Reply to: "Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion".
     J Hepatol. 2021 Feb 20. pii: S0168-8278(21)00114.
     PubMed    
     
     
     
131. BOYER JL, Soroka CJ
     Bile formation and Secretion: An update.
     J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00111.
     PubMed     Abstract available
     
     
     
132. MALLET V
     Intravenous ketamine and progressive cholangiopathy in Covid-19 patients.
     J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00107.
     PubMed    
     
     
     
133. CASOLINO R, Braconi C
     CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma.
     J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00045.
     PubMed    
     
     
     
134. BARTOLI A, Gitto S, Sighinolfi P, Cursaro C, et al
     PRIMARY BILIARY CHOLANGITIS ASSOCIATED WITH SARS-COV2 INFECTION.
     J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00106.
     PubMed    
     
     
     
135. ROESSLER S, Edeline J, Schirmacher P, Coulouarn C, et al
     Integrative genomics highlights opportunities for innovative therapies targeting the tumor microenvironment in gallbladder cancer.
     J Hepatol. 2021 Feb 16. pii: S0168-8278(21)00007.
     PubMed    
     
     
     
136. FABRIS L, Cadamuro M, Fouassier L
     Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche.
     J Hepatol. 2021 Feb 11. pii: S0168-8278(20)33892.
     PubMed    
     
     
     
137. CORNBERG M, Buti M, Eberhardt CS, Grossi PA, et al
     EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
     J Hepatol. 2021 Feb 6. pii: S0168-8278(21)00081.
     PubMed     Abstract available
     
     
     
138. BEAUFRERE A, Calderaro J, Paradis V
     Combined hepatocellular-cholangiocarcinoma: An update.
     J Hepatol. 2021 Feb 2. pii: S0168-8278(21)00084.
     PubMed     Abstract available
     
     
     January 2021
139. CONDE DE LA ROSA L, Garcia-Ruiz C, Vallejo C, Baulies A, et al
     STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
     J Hepatol. 2021 Jan 27. pii: S0168-8278(21)00040.
     PubMed     Abstract available
     
     
     
140. JAVITT NB
     Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion.
     J Hepatol. 2021 Jan 25. pii: S0168-8278(21)00044.
     PubMed    
     
     
     
141. SCHATTENBERG JM, Pares A, Kowdley KV, Heneghan MA, et al
     A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
     J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00022.
     PubMed     Abstract available
     
     
     
142. RAGGI C, Taddei ML, Sacco E, Navari N, et al
     Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma.
     J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00024.
     PubMed     Abstract available
     
     
     
143. RAHIM MN, Theocharidou E, Yen Lau KG, Ahmed R, et al
     Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients.
     J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00005.
     PubMed     Abstract available
     
     
     
144. NAYAGAM JS, Strautnieks S, Joshi D, Thompson RJ, et al
     Challenges in understanding the consequences of variants in ABCB4 gene.
     J Hepatol. 2021;74:242-243.
     PubMed    
     
     
     
145. STATTERMAYER AF, Ferenci P, Trauner M
     Reply to: "Challenges in understanding the consequences of variants in ABCB4 gene".
     J Hepatol. 2021;74:244-245.
     PubMed    
     
     
     December 2020
146. SARKAR M, Grab J, Irani RA
     Reply to: "Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?"
     J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33806.
     PubMed    
     
     
     
147. PHILLIPS J, Senaratne S
     Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?
     J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33694.
     PubMed    
     
     
     
148. VASAVAN T, Deepak S, Jayawardane IA, Lucchini M, et al
     Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations.
     J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33825.
     PubMed     Abstract available
     
     
     
149. DIGGS LP, Ruf B, Ma C, Heinrich B, et al
     CD40-mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma.
     J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33824.
     PubMed     Abstract available
     
     
     
150. NEPAL C, Zhu B, O'Rourke CJ, Bhatt DK, et al
     Integrative molecular characterization of gallbladder cancer reveals microenvironment-associated subtypes.
     J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33820.
     PubMed     Abstract available
     
     
     November 2020
151. DWYER BJ, Jarman EJ, Gogoi-Tiwari J, Ferreira-Gonzalez S, et al
     TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression.
     J Hepatol. 2020 Nov 19. pii: S0168-8278(20)33771.
     PubMed     Abstract available
     
     
     
152. HUANG YH, Zhang CZ, Huang QS, Yeong J, et al
     Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
     J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33763.
     PubMed     Abstract available
     
     
     
153. STEIN S, Henze L, Poch T, Carambia A, et al
     IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.
     J Hepatol. 2020 Nov 13. pii: S0168-8278(20)33759.
     PubMed     Abstract available
     
     
     October 2020
154. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
     Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia.
     J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33690.
     PubMed     Abstract available
     
     
     
155. CARBONE M, Ronca V, Invernizzi P
     Reply to: "A spotlight on natural killer cells in primary biliary cholangitis".
     J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33663.
     PubMed    
     
     
     
156. HYDES T, Khakoo SI
     A spotlight on natural killer cells in primary biliary cholangitis.
     J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33595.
     PubMed    
     
     
     
157. CAI SY, Yu D, Soroka CJ, Wang J, et al
     Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
     J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33680.
     PubMed     Abstract available
     
     
     September 2020
158. DYSON JK, Jones DEJ
     UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice.
     J Hepatol. 2020;73:499-501.
     PubMed    
     
     
     July 2020
159. TRAUNER M
     Effective medical treatments for PSC needed ASAP - is AESOP the answer?
     J Hepatol. 2020;73:12-14.
     PubMed    
     
     
     June 2020
160. HARMS MH, van Buuren HR, van der Meer AJ
     Reply to: "Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience".
     J Hepatol. 2020;72:1211-1212.
     PubMed    
     
     
     
161. CORPECHOT C, Rousseau A, Chazouilleres O
     Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience.
     J Hepatol. 2020;72:1210-1211.
     PubMed    
     
     
     April 2020
162. MAZUMDER NR, Celaj S, Atiemo K, Daud A, et al
     Liver-related mortality is similar among men and women with cirrhosis.
     J Hepatol. 2020 Apr 25. pii: S0168-8278(20)30235.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge.